TOSS, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.592
AS - Asia 8.579
EU - Europa 6.137
SA - Sud America 1.340
Continente sconosciuto - Info sul continente non disponibili 279
AF - Africa 259
OC - Oceania 56
Totale 31.242
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.166
SG - Singapore 2.463
CN - Cina 2.006
IT - Italia 1.840
GB - Regno Unito 1.108
VN - Vietnam 1.074
HK - Hong Kong 988
BR - Brasile 983
DE - Germania 574
SE - Svezia 555
BD - Bangladesh 510
IE - Irlanda 342
FI - Finlandia 332
RU - Federazione Russa 308
KR - Corea 277
FR - Francia 268
IN - India 250
CA - Canada 216
ID - Indonesia 197
TR - Turchia 130
UA - Ucraina 125
AR - Argentina 114
MX - Messico 112
NL - Olanda 107
JP - Giappone 101
IQ - Iraq 98
BG - Bulgaria 93
ES - Italia 80
PL - Polonia 74
ZA - Sudafrica 68
EC - Ecuador 61
CO - Colombia 60
PK - Pakistan 57
MY - Malesia 52
AU - Australia 51
EG - Egitto 48
TW - Taiwan 45
AT - Austria 44
LT - Lituania 44
AE - Emirati Arabi Uniti 39
VE - Venezuela 36
MA - Marocco 35
IR - Iran 32
CL - Cile 30
PH - Filippine 30
SA - Arabia Saudita 30
UZ - Uzbekistan 27
BE - Belgio 26
KE - Kenya 25
PY - Paraguay 24
CR - Costa Rica 23
CZ - Repubblica Ceca 20
JO - Giordania 20
NP - Nepal 19
TH - Thailandia 18
DK - Danimarca 17
NO - Norvegia 17
AZ - Azerbaigian 16
HU - Ungheria 15
IL - Israele 15
MD - Moldavia 15
SI - Slovenia 15
TN - Tunisia 15
CH - Svizzera 14
GR - Grecia 14
JM - Giamaica 14
BO - Bolivia 13
DZ - Algeria 12
PA - Panama 12
RO - Romania 12
AL - Albania 11
DO - Repubblica Dominicana 10
HR - Croazia 10
PE - Perù 10
RS - Serbia 10
SY - Repubblica araba siriana 10
KG - Kirghizistan 9
HN - Honduras 8
KZ - Kazakistan 8
LB - Libano 8
LV - Lettonia 8
OM - Oman 8
PT - Portogallo 8
CI - Costa d'Avorio 7
CY - Cipro 7
ET - Etiopia 7
MT - Malta 7
UY - Uruguay 7
AO - Angola 6
BH - Bahrain 6
BY - Bielorussia 6
GE - Georgia 6
SV - El Salvador 6
EU - Europa 5
GH - Ghana 5
MK - Macedonia 5
NI - Nicaragua 5
NZ - Nuova Zelanda 5
SN - Senegal 5
XK - ???statistics.table.value.countryCode.XK??? 5
Totale 30.889
Salva come PNG Salva come JPEG
Città #
Ashburn 1.806
Singapore 1.433
Santa Clara 1.385
Fairfield 1.115
Hong Kong 957
San Jose 839
Chandler 751
Hefei 669
Council Bluffs 575
Woodbridge 537
Seattle 477
Houston 435
Southend 395
Cambridge 390
Beijing 370
Ho Chi Minh City 343
Dublin 337
Nyköping 336
London 333
Wilmington 332
Los Angeles 300
Dallas 281
New York 262
Helsinki 260
Seoul 258
Hanoi 251
Dearborn 212
Modena 207
Ann Arbor 206
Chicago 197
Milan 178
The Dalles 164
Jakarta 138
Lauterbourg 123
Bologna 112
Jacksonville 107
San Diego 107
Princeton 95
São Paulo 93
Munich 90
Sofia 90
Moscow 89
Buffalo 85
Tokyo 84
Boardman 82
Rome 82
Shanghai 79
Frankfurt am Main 75
Orem 73
Salt Lake City 67
Bremen 58
Eugene 52
Izmir 52
Warsaw 52
Baghdad 51
Columbus 51
Da Nang 51
Haiphong 50
Redwood City 49
Fremont 44
Phoenix 44
Toronto 44
Manchester 42
Atlanta 41
Reggio Emilia 41
Montreal 40
Brooklyn 39
Kent 39
Nuremberg 39
Dong Ket 38
Johannesburg 36
Mexico City 36
Naples 36
Guangzhou 35
Chennai 34
Rio de Janeiro 33
Denver 32
Portsmouth 32
Belo Horizonte 31
Lappeenranta 31
Parma 31
Redondo Beach 31
Stockholm 31
Mumbai 30
Florence 29
San Giuliano Milanese 28
Dhaka 27
Düsseldorf 27
Miami 27
Poplar 27
Philadelphia 26
Turku 26
Falls Church 25
Sydney 25
Boston 24
Madrid 24
Miano 24
Tashkent 23
Turin 23
Vienna 23
Totale 20.046
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 636
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 489
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 480
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 465
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 428
Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: Hybrid Posters 420
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 402
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 400
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 374
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 373
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 357
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 354
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 351
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 350
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 342
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 335
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 327
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 322
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 317
NUT midline carcinoma of the head and neck: current perspectives 311
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 310
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 305
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 303
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 302
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 298
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 298
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 296
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 296
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 293
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 293
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 290
Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study 290
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 287
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 282
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 280
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 277
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 275
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 275
Hereditary ovarian cancers: State of the art 275
Combined hormonal contraceptives in BRCA gene mutation carriers: why not? 267
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 262
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 260
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 259
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 257
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 254
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 253
Chemoprevention strategies for high risk women 249
Characterization of new ATM deletion associated with hereditary breast cancer 249
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 247
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 246
Twenty-years experience with de novo metastatic breast cancer 244
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 244
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 243
The role of exosomes in breast cancer diagnosis 243
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 241
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study 238
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 237
PARP Inhibitors for Breast Cancer Treatment A Review 235
Radiological screening programs for women at high risk of developing breast cancer 235
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis 234
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 233
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 232
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial 232
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 232
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 230
Molecular characterization and targeted therapeutic approaches in breast cancer 226
Breast ultrasound in high-risk women 225
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 223
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 222
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 218
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 218
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 217
PARP inhibitors for the treatment of ovarian cancer 211
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 206
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 202
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 201
Management of PALB2-associated breast cancer: A literature review and case report 198
Personalized Systemic Therapies in Hereditary Cancer Syndromes 198
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 197
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 193
Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less 191
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 190
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 190
Occult breast cancer: the uncommon presentation of a common disease 185
COVID-related disruption in mammographic screening: a year later. 182
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 181
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group 180
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 177
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 177
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 176
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 174
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 174
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 171
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 170
Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) 167
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer 167
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 161
LOW-FREQUENCY ALLELE VARIANTS IN NGS MULTI-GENE PANELS FOR HEREDITARY CANCER TESTING: ARTIFACTS, CHIP OR MOSAICS? MANAGING THE RESULTS IN THE LABORATORY ROUTINE 161
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 161
The spectrum of fancm protein truncating variants in European breast cancer cases 160
Totale 26.364
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122.319
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.319
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.764 0 164 141 82 68 133 90 102 250 164 336 234
2022/20232.396 268 301 169 192 225 259 48 180 526 35 98 95
2023/20241.756 92 92 97 175 260 144 230 229 68 69 114 186
2024/20255.933 141 59 120 302 986 765 584 372 703 389 644 868
2025/202612.860 900 476 1.134 1.391 1.504 824 1.575 708 1.232 1.257 1.077 782
2026/20271.277 495 782 0 0 0 0 0 0 0 0 0 0
Totale 31.242